Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Godavari DrugsBOM:530317 -0.49%54 PB Ratio is 1.37 as of Aug. 12, 2026, which is 16% below its 10-year median of 1.64. GuruFocus rates BOM:530317 with a GF Score™ of 54/100 and a GF Value™ of ₹72.35 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 920 Drug Manufacturers companies, Godavari Drugs ranks better than 65.65% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Godavari Drugs's share price is ₹102.50. Godavari Drugs's Book Value per Share for the quarter that ended in Mar. 2026 was ₹74.85. Hence, Godavari Drugs's PB Ratio of today is 1.37.
The historical rank and industry rank for Godavari Drugs's PB Ratio or its related term are showing as below:
BOM:530317'
s PB Ratio Range Over the Past 10 Years
Min: 0.42 Med: 1.64 Max: 2.35
Current: 1.37
During the past 13 years, Godavari Drugs's highest PB Ratio was 2.35. The lowest was 0.42. And the median was 1.64.
BOM:530317's PB Ratio is ranked better than 65.65% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BOM:530317: 1.37
During the past 12 months, Godavari Drugs's average Book Value Per Share Growth Rate was 30.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 19.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 17.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 14.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Godavari Drugs was 21.90% per year. The lowest was -24.30% per year. And the median was 13.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Godavari Drugs PB Ratio Related Terms
Godavari Drugs PB Ratio Historical Data
* Premium members only.
The historical data trend for Godavari Drugs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Godavari Drugs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Godavari Drugs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Godavari Drugs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Godavari Drugs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Godavari Drugs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Godavari Drugs (BOM:530317) has a PB Ratio of 1.37 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Godavari Drugs and its competitors. This is 16% below median its historical median of 1.64. Over the past decade, Godavari Drugs' PB Ratio has ranged from 0.42 to 2.35. According to the industry distribution chart, Godavari Drugs ranks #316 out of 920 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is Godavari Drugs' PB Ratio too high?
Godavari Drugs' current PB Ratio of 1.37 is 16% below median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.42 to a high of 2.35. The Drug Manufacturers industry median PB Ratio is 1.98. Godavari Drugs' value of 1.37 is 30.8% below this industry median. Based on the distribution chart, Godavari Drugs ranks #316 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Godavari Drugs has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Godavari Drugs' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Godavari Drugs ranks #316 out of 920 companies for PB Ratio. This puts Godavari Drugs in the upper half of its industry. The industry median PB Ratio is 1.98. Godavari Drugs' value of 1.37 is 30.8% below this benchmark. Historically, Godavari Drugs' own PB Ratio has ranged from 0.42 to 2.35 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 1.98, Godavari Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Godavari Drugs's current PB Ratio of 1.37 is 30.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Godavari Drugs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Godavari Drugs's current PB Ratio is 1.37, which is 16% below median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Godavari Drugs stock overvalued right now?
Based on GuruFocus' analysis, Godavari Drugs (BOM:530317) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹72.35, compared to a current price of ₹102.50 — trading 41.7% above its estimated fair value. The current PB Ratio is 1.37, which is 16% below median its 10-year median of 1.64 and 30.8% below the Drug Manufacturers industry median of 1.98. Godavari Drugs' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Godavari Drugs (BOM:530317), the current PB Ratio is 1.37 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Godavari Drugs (BOM:530317) Overvalued in 2026?
Based on GuruFocus' analysis, Godavari Drugs stock appears to be overvalued.
The current stock price of ₹102.50 is trading 41.7% above its estimated GF Value™ of ₹72.35.
GuruFocus considers Godavari Drugs to be Significantly Overvalued.
Key valuation signals for BOM:530317:
PB Ratio: 1.37 (16% below median its 10-year median of 1.64)
GF Value™: ₹72.35 vs. price of ₹102.50 (41.7% above fair value)
Industry Position: 30.8% below the Drug Manufacturers median (#316 of 920)
No single metric tells the full story. See the BOM:530317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Godavari Drugs Ltd is an India-based pharmaceutical company. It is principally engaged in manufacturing of APl's, intermediates and fine chemicals,. The firm's product includes Ciprofloxacin hydrochloride, ciprofloxacin, ciprofloxacin lactate, ciprofloxacin lactate, and Others. The company operates only one segment which is the manufacture and sale of Active Pharmaceutical Ingredients (API) and its intermediates.
54GF Score
Get the complete analysis for BOM:530317
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530317 has been successfully added to your 
